A Consensus Statement on acromegaly therapeutic outcomes

Imagem de Miniatura
Arquivos
art_MELMED_A_Consensus_Statement_on_acromegaly_therapeutic_outcomes_2018.PDF (1.08 MB)
Citações na Scopus
393
Tipo de produção
article
Data de publicação
2018
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
NATURE PUBLISHING GROUP
Autores
MELMED, Shlomo
CHANSON, Philippe
KLIBANSKI, Anne
CASANUEVA, Felipe F.
WASS, John A. H.
STRASBURGER, Christian J.
LUGER, Anton
CLEMMONS, David R.
GIUSTINA, Andrea
Citação
NATURE REVIEWS ENDOCRINOLOGY, v.14, n.9, p.552-561, 2018
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
The 11th Acromegaly Consensus Conference in April 2017 was convened to update recommendations on therapeutic outcomes for patients with acromegaly. Consensus guidelines on the medical management of acromegaly were last published in 2014; since then, new pharmacological agents have been developed and new approaches to treatment sequencing have been considered. Thirty-seven experts in the management of patients with acromegaly reviewed the current literature and assessed changes in drug approvals, clinical practice standards and clinical opinion. They considered current treatment outcome goals with a focus on the impact of current and emerging somatostatin receptor ligands, growth hormone receptor antagonists and dopamine agonists on biochemical, clinical, tumour mass and surgical outcomes. The participants discussed factors that would determine pharmacological choices as well as the proposed place of each agent in the guidelines. We present consensus recommendations highlighting how acromegaly management could be optimized in clinical practice.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/28347
Referências
  1. Abu Dabrh A, 2015, ENDOCR PRACT, V21, P943, DOI 10.4158/EP14574.OR
  2. Anik I, 2017, WORLD NEUROSURG, V108, P278, DOI 10.1016/j.wneu.2017.08.182
  3. Arafat AM, 2008, J CLIN ENDOCR METAB, V93, P1254, DOI 10.1210/jc.2007-2084
  4. Attal P, 2010, J CLIN ENDOCR METAB, V95, P483, DOI 10.1210/jc.2009-1912
  5. Ayuk J, 2004, J CLIN ENDOCR METAB, V89, P1613, DOI 10.1210/jc.2003-031584
  6. Babu H, 2017, NEUROSURGERY, V81, P357, DOI 10.1093/neuros/nyx020
  7. Balili I, 2014, PITUITARY, V17, P500, DOI 10.1007/s11102-013-0534-9
  8. Beckers A, 2015, ENDOCR-RELAT CANCER, V22, P353, DOI 10.1530/ERC-15-0038
  9. Berg C, 2010, J CLIN ENDOCR METAB, V95, P3648, DOI 10.1210/jc.2009-2570
  10. Bevan JS, 2005, J CLIN ENDOCR METAB, V90, P1856, DOI 10.1210/jc.2004-1093
  11. Bianchi A, 2009, J CLIN ENDOCR METAB, V94, P2015, DOI 10.1210/jc.2008-1337
  12. Bidlingmaier M, 2010, GROWTH HORM IGF RES, V20, P19, DOI 10.1016/j.ghir.2009.09.005
  13. Bonadonna S, 2005, J BONE MINER RES, V20, P1837, DOI 10.1359/JBMR.050603
  14. Brzana J, 2013, PITUITARY, V16, P490, DOI 10.1007/s11102-012-0445-1
  15. Brzana JA, 2012, PITUITARY, V15, P562, DOI 10.1007/s11102-011-0369-1
  16. Buhk JH, 2010, J CLIN ENDOCR METAB, V95, P552, DOI 10.1210/jc.2009-1239
  17. Bystrom C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043457
  18. Carlsen SM, 2008, J CLIN ENDOCR METAB, V93, P2984, DOI 10.1210/jc.2008-0315
  19. Carmichael JD, 2014, J CLIN ENDOCR METAB, V99, P1825, DOI 10.1210/jc.2013-3757
  20. Carmichael JD, 2009, J CLIN ENDOCR METAB, V94, P523, DOI 10.1210/jc.2008-1371
  21. Caron PJ, 2014, J CLIN ENDOCR METAB, V99, P1282, DOI 10.1210/jc.2013-3318
  22. Casanueva FF, 2017, PITUITARY, V20, P489, DOI 10.1007/s11102-017-0838-2
  23. Chanson P, 2016, J CLIN ENDOCR METAB, V101, P3450, DOI 10.1210/jc.2016-1257
  24. Chen CJ, 2017, ACTA NEUROCHIR, V159, P2193, DOI 10.1007/s00701-017-3318-6
  25. Chin SO, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2014-006898
  26. Claessen KMJA, 2013, J CLIN ENDOCR METAB, V98, P4808, DOI 10.1210/jc.2013-2695
  27. Clemmons DR, 2011, CLIN CHEM, V57, P555, DOI 10.1373/clinchem.2010.150631
  28. Clemmons DR, 2011, CLIN CHIM ACTA, V412, P403, DOI 10.1016/j.cca.2010.11.008
  29. Colao A, 2006, EUR J ENDOCRINOL, V154, P467, DOI 10.1530/eje.1.02112
  30. Colao A, 2014, J CLIN ENDOCR METAB, V99, P791, DOI 10.1210/jc.2013-2480
  31. Colao A, 2004, ENDOCR REV, V25, P102, DOI 10.1210/er.2002-0022
  32. Colao A, 2016, PITUITARY, V19, P235, DOI 10.1007/s11102-015-0684-z
  33. Colao A, 2016, PITUITARY, V19, P210, DOI 10.1007/s11102-015-0677-y
  34. Colao A, 2009, J CLIN ENDOCR METAB, V94, P3746, DOI 10.1210/jc.2009-0941
  35. Cuevas-Ramos D, 2015, J CLIN ENDOCR METAB, V100, P122, DOI 10.1210/jc.2014-2468
  36. Daly AF, 2010, J CLIN ENDOCR METAB, V95, pE373, DOI 10.1210/jc.2009-2556
  37. Dekkers OM, 2008, J CLIN ENDOCR METAB, V93, P61, DOI 10.1210/jc.2007-1191
  38. Dillard TH, 2011, PITUITARY, V14, P80, DOI 10.1007/s11102-010-0264-1
  39. Drake WM, 2003, EUR J ENDOCRINOL, V149, P521, DOI 10.1530/eje.0.1490521
  40. Duarte FH, 2015, J CLIN ENDOCR METAB, V100, P1863, DOI 10.1210/jc.2014-3913
  41. Fleseriu M, 2015, ENDOCR PRACT, V21, P668, DOI 10.4158/EP14575.DSCR
  42. Franck SE, 2017, EUR J ENDOCRINOL, V176, P421, DOI 10.1530/EJE-16-0956
  43. Frara S, 2016, TRENDS ENDOCRIN MET, V27, P470, DOI 10.1016/j.tem.2016.04.014
  44. Freda PU, 2015, ENDOCR PRACT, V21, P264, DOI 10.4158/EP14330.OR
  45. Gadelha MR, 2017, PITUITARY, V20, P100, DOI 10.1007/s11102-017-0791-0
  46. Gadelha MR, 2014, LANCET DIABETES ENDO, V2, P875, DOI 10.1016/S2213-8587(14)70169-X
  47. Giustina A, 2000, J CLIN ENDOCR METAB, V85, P526, DOI 10.1210/jc.85.2.526
  48. Giustina A, 2017, J ENDOCRINOL INVEST, V40, P577, DOI 10.1007/s40618-017-0614-1
  49. Giustina A, 2017, J CLIN ENDOCR METAB, V102, P2454, DOI 10.1210/jc.2017-00142
  50. Giustina A, 2016, PITUITARY, V19, P39, DOI 10.1007/s11102-015-0681-2
  51. Giustina A, 2014, NAT REV ENDOCRINOL, V10, P243, DOI 10.1038/nrendo.2014.21
  52. Giustina A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036411
  53. Giustina A, 2009, EUR J ENDOCRINOL, V161, P331, DOI 10.1530/EJE-09-0372
  54. Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD
  55. Hazer DB, 2013, J NEUROSURG, V119, P1467, DOI 10.3171/2013.8.JNS13224
  56. Hernandez-Ramirez LC, 2015, J CLIN ENDOCR METAB, V100, pE1242, DOI 10.1210/jc.2015-1869
  57. Higham CE, 2009, J CLIN ENDOCR METAB, V94, P2459, DOI 10.1210/jc.2008-2086
  58. Holdaway IM, 2008, EUR J ENDOCRINOL, V159, P89, DOI 10.1530/EJE-08-0267
  59. Jaffrain-Rea ML, 2003, EUR J ENDOCRINOL, V148, P193, DOI 10.1530/eje.0.1480193
  60. Jane JA, 2011, J CLIN ENDOCR METAB, V96, P2732, DOI 10.1210/jc.2011-0554
  61. Katznelson L, 2014, J CLIN ENDOCR METAB, V99, P3933, DOI 10.1210/jc.2014-2700
  62. Kiseljak-Vassiliades K, 2015, ENDOCRINE, V49, P231, DOI 10.1007/s12020-014-0383-y
  63. Ku CR, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003808
  64. Kuhn E, 2017, PITUITARY, V20, P121, DOI 10.1007/s11102-016-0782-6
  65. Kuhn E, 2015, EUR J ENDOCRINOL, V173, P693, DOI 10.1530/EJE-15-0500
  66. Lois K, 2015, PITUITARY, V18, P568, DOI 10.1007/s11102-014-0586-5
  67. Machado EO, 2008, GROWTH HORM IGF RES, V18, P389, DOI 10.1016/j.ghir.2008.02.001
  68. Maffezzoni F, 2016, GROWTH HORM IGF RES, V30-31, P58, DOI 10.1016/j.ghir.2016.10.001
  69. Maione L, 2017, EUR J ENDOCRINOL, V176, P645, DOI 10.1530/EJE-16-1064
  70. Maione L, 2012, J CLIN ENDOCR METAB, V97, pE1714, DOI 10.1210/jc.2012-1833
  71. Mangupli R, 2014, PITUITARY, V17, P495, DOI 10.1007/s11102-013-0533-x
  72. Marazuela M, 2011, J CLIN ENDOCR METAB, V96, pE251, DOI 10.1210/jc.2010-1742
  73. Mavromati M, 2017, J CLIN ENDOCR METAB, V102, P2844, DOI 10.1210/jc.2017-00202
  74. Mazziotti G, 2008, J CLIN ENDOCR METAB, V93, P4649, DOI 10.1210/jc.2008-0791
  75. Mazziotti G, 2015, ENDOCRIN METAB CLIN, V44, P171, DOI 10.1016/j.ecl.2014.10.014
  76. Mazziotti G, 2015, J CLIN ENDOCR METAB, V100, P384, DOI 10.1210/jc.2014-2937
  77. Mazziotti G, 2010, PITUITARY, V13, P60, DOI 10.1007/s11102-009-0169-z
  78. Mazziotti G, 2009, J CLIN ENDOCR METAB, V94, P1500, DOI 10.1210/jc.2008-2332
  79. Melmed S, 2005, J CLIN ENDOCR METAB, V90, P4405, DOI 10.1210/jc.2004-2466
  80. Melmed S, 2006, NEW ENGL J MED, V355, P2558, DOI 10.1056/NEJMra062453
  81. Melmed S, 2016, J CLIN ENDOCR METAB, V101, P769, DOI 10.1210/jc.2015-3653
  82. Melmed S, 2016, NAT REV ENDOCRINOL, V12, P90, DOI 10.1038/nrendo.2015.196
  83. Melmed S, 2015, J CLIN ENDOCR METAB, V100, P1699, DOI 10.1210/jc.2014-4113
  84. Melmed S, 2010, PITUITARY, V13, P18, DOI 10.1007/s11102-009-0191-1
  85. Melmed S, 2009, J CLIN INVEST, V119, P3189, DOI 10.1172/JCI39375
  86. Mercado M, 2007, CLIN ENDOCRINOL, V66, P859, DOI 10.1111/j.1365-2265.2007.02825.x
  87. Mercado M, 2014, J CLIN ENDOCR METAB, V99, P4438, DOI 10.1210/jc.2014-2670
  88. Mortini P, 2018, ENDOCRINE, V59, P72, DOI 10.1007/s12020-017-1458-3
  89. Muhammad A, 2016, EUR J ENDOCRINOL, V174, P663, DOI 10.1530/EJE-15-1150
  90. Murray RD, 2008, J CLIN ENDOCR METAB, V93, P2957, DOI 10.1210/jc.2008-0027
  91. Neggers SJCMM, 2014, J CLIN ENDOCR METAB, V99, P3644, DOI 10.1210/jc.2014-2032
  92. Neggers SJCMM, 2009, EUR J ENDOCRINOL, V160, P529, DOI 10.1530/EJE-08-0843
  93. Nunes VS, 2015, PITUITARY, V18, P500, DOI 10.1007/s11102-014-0602-9
  94. Oldfield EH, 2017, J NEUROSURG, V126, P1959, DOI 10.3171/2016.8.JNS161123
  95. Parkinson C, 2003, J CLIN ENDOCR METAB, V88, P5650, DOI 10.1210/jc.2003-030772
  96. Pivonello R, 2017, PITUITARY, V20, P46, DOI 10.1007/s11102-017-0797-7
  97. Potorac I, 2015, ENDOCR-RELAT CANCER, V22, P169, DOI 10.1530/ERC-14-0305
  98. Puig-Domingo M, 2010, J CLIN ENDOCR METAB, V95, P4973, DOI 10.1210/jc.2010-0573
  99. Ragonese M, 2018, J ENDOCRINOL INVEST, V41, P575, DOI 10.1007/s40618-017-0773-0
  100. Reid TJ, 2015, PITUITARY, V18, P808, DOI 10.1007/s11102-015-0657-2
  101. Ribeiro-Oliveira A, 2013, J CLIN ENDOCR METAB, V98, P2959, DOI 10.1210/jc.2013-1581
  102. Ritvonen E, 2016, ENDOCR-RELAT CANCER, V23, P469, DOI 10.1530/ERC-16-0106
  103. Rokkas T, 2008, WORLD J GASTROENTERO, V14, P3484, DOI 10.3748/wjg.14.3484
  104. Salvatori R, 2010, PITUITARY, V13, P115, DOI 10.1007/s11102-009-0207-x
  105. Sandret L, 2011, J CLIN ENDOCR METAB, V96, P1327, DOI 10.1210/jc.2010-2443
  106. Schilbach K, 2017, PITUITARY, V20, P33, DOI 10.1007/s11102-017-0792-z
  107. Schmid HA, 2016, ENDOCRINE, V53, P210, DOI 10.1007/s12020-016-0895-8
  108. Sherlock M, 2009, J CLIN ENDOCR METAB, V94, P4216, DOI 10.1210/jc.2009-1097
  109. Sherlock M, 2010, ENDOCR REV, V31, P301, DOI 10.1210/er.2009-0033
  110. Shimon I, 2001, NEUROSURGERY, V48, P1239, DOI 10.1097/00006123-200106000-00008
  111. Shin MS, 2013, NEUROSURGERY, V73, P473, DOI 10.1227/01.neu.0000431480.87160.84
  112. Sievers C, 2015, PITUITARY, V18, P916, DOI 10.1007/s11102-015-0673-2
  113. Silva PPB, 2017, EUR J ENDOCRINOL, V177, P409, DOI 10.1530/EJE-17-0468
  114. Starke RM, 2013, J CLIN ENDOCR METAB, V98, P3190, DOI 10.1210/jc.2013-1036
  115. Stone JC, 2014, PITUITARY, V17, P284, DOI 10.1007/s11102-013-0504-2
  116. Swiglo BA, 2008, J CLIN ENDOCR METAB, V93, P666, DOI 10.1210/jc.2007-1907
  117. Theodoropoulou M, 2013, FRONT NEUROENDOCRIN, V34, P228, DOI 10.1016/j.yfrne.2013.07.005
  118. Trainer PJ, 2000, NEW ENGL J MED, V342, P1171, DOI 10.1056/NEJM200004203421604
  119. Tritos NA, 2017, EUR J ENDOCRINOL, V176, P213, DOI 10.1530/EJE-16-0697
  120. van der Lely AJ, 2012, J CLIN ENDOCR METAB, V97, P1589, DOI 10.1210/jc.2011-2508
  121. van der Lely AJ, 2017, PITUITARY, V20, P692, DOI 10.1007/s11102-017-0835-5
  122. van der Lely AJ, 2016, EUR J ENDOCRINOL, V175, P239, DOI 10.1530/EJE-16-0008
  123. van der Lely AJ, 2001, LANCET, V358, P1754, DOI 10.1016/S0140-6736(01)06844-1
  124. Verrua E., 2014, INT J ENDOCRINOL, V2014
  125. Neto LV, 2009, J CLIN ENDOCR METAB, V94, P1931, DOI 10.1210/jc.2008-1826
  126. Wassenaar MJE, 2011, EUR J ENDOCRINOL, V164, P475, DOI 10.1530/EJE-10-1005
  127. Webb SM, 2006, EUR J ENDOCRINOL, V155, P269, DOI 10.1530/eje.1.02214

Coleções
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/25